TG Therapeutics, Inc. (TGTX) Financials

$29.73

north_east
$2.06 (7.44%)
Day's range
$28.41
Day's range
$30.68

TGTX Income statement / Annual

Last year (2023), TG Therapeutics, Inc.'s total revenue was $233.66 M, an increase of 8,290.02% from the previous year. In 2023, TG Therapeutics, Inc.'s net income was $12.67 M. See TG Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $233.66 M $2.79 M $6.69 M $152,000.00 $152,000.00 $152,000.00 $152,381.00 $152,381.00 $152,381.00 $152,381.00
Cost of Revenue $14.13 M $265,000.00 $790,000.00 $374,000.00 $282,000.00 $88,000.00 $82,355.00 $62,960.00 $0.00 $0.00
Gross Profit $219.53 M $2.52 M $5.90 M -$222,000.00 -$130,000.00 $64,000.00 $70,026.00 $89,421.00 $152,381.00 $152,381.00
Gross Profit Ratio 0.94 0.9 0.88 -1.46 -0.86 0.42 0.46 0.59 1 1
Research and Development Expenses $76.19 M $112.13 M $198.53 M $151.93 M $148.37 M $153.79 M $96.89 M $66.49 M $43.45 M $31.35 M
General & Administrative Expenses $122.71 M $83.23 M $152.14 M $121.81 M $20.84 M $20.76 M $21.98 M $12.63 M $19.89 M $24.52 M
Selling & Marketing Expenses $0.00 $64.05 M $90.86 M $41.52 M $0.00 -$5.60 M -$5.65 M -$2.74 M -$4.26 M -$8.73 M
Selling, General & Administrative Expenses $122.71 M $83.23 M $152.14 M $121.81 M $20.84 M $20.76 M $21.98 M $12.63 M $19.89 M $24.52 M
Other Expenses $0.00 $4.70 M $2.31 M $542,000.00 $1.47 M $61,000.00 -$58,739.00 $393,202.00 $1.03 M $815,467.00
Operating Expenses $198.90 M $195.36 M $350.67 M $273.75 M $169.21 M $174.55 M $118.86 M $79.12 M $63.33 M $55.87 M
Cost And Expenses $213.03 M $195.62 M $351.46 M $273.75 M $169.21 M $174.55 M $118.86 M $79.12 M $63.33 M $55.87 M
Interest Income $0.00 $10.19 M $5.64 M $6.33 M $5.29 M $857,000.00 $294,478.00 $323,032.00 $174,653.00 $55,049.00
Interest Expense $12.62 M $10.19 M $5.64 M $6.33 M $5.29 M $1.73 M $1.14 M $0.00 $972,736.00 $930,701.00
Depreciation & Amortization $423,000.00 $515,000.00 $494,000.00 $374,000.00 $282,000.00 $88,000.00 $82,355.00 $62,960.00 $15,452.00 $3,931.00
EBITDA $26.10 M -$187.63 M -$341.97 M -$272.68 M -$168.50 M -$173.39 M -$118.39 M -$78.91 M -$63.16 M -$55.72 M
EBITDA Ratio 0.11 -67.56 -51.2 -1796.39 -1102.53 -1146.79 -779.05 -518.23 -406.72 -359.96
Operating Income Ratio 0.09 -69.24 -51.54 -1799.96 -1112.2 -1147.37 -779.05 -518.23 -414.62 -365.67
Total Other Income/Expenses Net -$7.57 M -$5.50 M -$3.33 M -$5.79 M -$3.82 M $918,000.00 $235,988.00 $716,000.00 $231,370.00 -$60,185.00
Income Before Tax $13.06 M -$198.34 M -$348.10 M -$279.38 M -$172.87 M -$173.48 M -$118.48 M -$78.25 M -$62.95 M -$55.78 M
Income Before Tax Ratio 0.06 -71.22 -52.04 -1838.03 -1137.31 -1141.33 -777.5 -513.53 -413.1 -366.06
Income Tax Expense $390,000.00 $5.50 M $7.45 M $6.50 M $6.48 M -$918,000.00 -$235,739.00 -$716,234.00 -$231,370.00 $60,185.00
Net Income $12.67 M -$203.83 M -$355.55 M -$285.88 M -$179.35 M -$173.48 M -$118.48 M -$78.25 M -$62.95 M -$55.78 M
Net Income Ratio 0.05 -73.19 -53.15 -1880.78 -1179.91 -1141.33 -777.5 -513.53 -413.1 -366.06
EPS 0.0893 -1.51 -2.69 -2.48 -2.03 -2.3 -1.91 -1.6 -1.38 -1.64
EPS Diluted 0.0853 -1.51 -2.69 -2.48 -2.03 -2.3 -1.91 -1.6 -1.38 -1.64
Weighted Average Shares Out $141.96 M $135.41 M $132.22 M $115.33 M $88.37 M $75.47 M $62.07 M $49.04 M $45.65 M $34.07 M
Weighted Average Shares Out Diluted $148.51 M $135.41 M $132.22 M $115.33 M $88.37 M $75.47 M $62.07 M $49.04 M $45.65 M $34.07 M
Link